Klinická evidence
Výčet klinických hodnocení léčby kouření, která doložila účinnost terapie:
Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, Ascher J, Russ C, Krishen A, Evins AE: Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016 Jun 18;387(10037):2507-20.
https://www.ncbi.nlm.nih.gov/pubmed/27116918
Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB Jr, Gong J, Williams KE, Reeves KR: Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. 2008 Aug;63(8):717-24. doi: 10.1136/thx.2007.090647. Epub 2008 Feb 8.
https://www.ncbi.nlm.nih.gov/pubmed/?term=%E2%80%A2Aubin+HJ+et+al.+Thora....
Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD 3rd, O'Neill BT: Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005 May 19;48(10):3474-7.
https://www.ncbi.nlm.nih.gov/pubmed/?term=Coe+JW+et+al.+J+Med+Chem.+2005....
Williams KE, Reeves KR, Billing CB Jr, Pennington AM, Gong J: A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin. 2007 Apr;23(4):793-801.
https://www.ncbi.nlm.nih.gov/pubmed/17407636
Jorenby DE, Hays JT, Rigotti NA, et al.: Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56–63.
https://www.ncbi.nlm.nih.gov/pubmed/?term=Jorenby+DE%2C+Hays+JT%2C+Rigot...
Gonzales D, Rennard SI, Nides M, et al.: Varenicline Phase 3 Study Group. Varenicline, an Jorenby DE, Hays JT, Rigotti NA, et al. Varenicline Phase 3 Study Group. Efficacy of varenicline alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47–55.
https://www.ncbi.nlm.nih.gov/pubmed/?term=Gonzales+D%2C+Rennard+SI%2C+Ni...
Nides M, Glover ED, Reus VI, Christen AG, Make BJ, Billing CB Jr, Williams KE: Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav. 2008 Nov-Dec;32(6):664-75.
(Studie popisující sloučená data ze srovnávacích studií míry ukončení kouření ve 12. týdnu) https://www.ncbi.nlm.nih.gov/pubmed/18442345
Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR: Varenicline Phase 3 Study Group: Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006 Jul 5;296(1):64-71.
(Studie prodloužené léčby: míra nepřetržité abstinence ve 24. týdnu a v 52. týdnu)
https://www.ncbi.nlm.nih.gov/pubmed/16820548
